New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Physicians’ Education Resource (PER ®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and information on the latest innovations in anti-VEGF ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...